- Home
- ASYS vs ZURA Comparison
ASYS vs ZURA Comparison
Compare ASYS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASYS
- ZURA
- Stock Information
- Founded
- ASYS 1981
- ZURA 2022
- Country
- ASYS United States
- ZURA United States
- Employees
- ASYS N/A
- ZURA N/A
- Industry
- ASYS Industrial Machinery/Components
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASYS Technology
- ZURA Health Care
- Exchange
- ASYS Nasdaq
- ZURA Nasdaq
- Market Cap
- ASYS 68.0M
- ZURA 69.9M
- IPO Year
- ASYS N/A
- ZURA N/A
- Fundamental
- Price
- ASYS $6.33
- ZURA $2.04
- Analyst Decision
- ASYS
- ZURA Buy
- Analyst Count
- ASYS 0
- ZURA 10
- Target Price
- ASYS N/A
- ZURA $12.67
- AVG Volume (30 Days)
- ASYS 81.9K
- ZURA 375.3K
- Earning Date
- ASYS 08-06-2025
- ZURA 08-14-2025
- Dividend Yield
- ASYS N/A
- ZURA N/A
- EPS Growth
- ASYS N/A
- ZURA N/A
- EPS
- ASYS N/A
- ZURA N/A
- Revenue
- ASYS $83,634,000.00
- ZURA N/A
- Revenue This Year
- ASYS N/A
- ZURA N/A
- Revenue Next Year
- ASYS $12.93
- ZURA N/A
- P/E Ratio
- ASYS N/A
- ZURA N/A
- Revenue Growth
- ASYS N/A
- ZURA N/A
- 52 Week Low
- ASYS $3.20
- ZURA $0.97
- 52 Week High
- ASYS $6.50
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- ASYS 67.35
- ZURA 65.78
- Support Level
- ASYS $5.82
- ZURA $1.44
- Resistance Level
- ASYS $6.44
- ZURA $2.09
- Average True Range (ATR)
- ASYS 0.41
- ZURA 0.14
- MACD
- ASYS 0.10
- ZURA 0.03
- Stochastic Oscillator
- ASYS 94.09
- ZURA 78.31
About ASYS Amtech Systems Inc.
Amtech Systems Inc is a manufacturer of capital equipment, including thermal processing and wafer polishing, and related consumables used in fabricating semiconductor devices, such as silicon carbide (SiC) and silicon power chips, electronic assemblies, and light-emitting diodes (LEDs). the company has two segments; based on the industries served: Thermal Processing Solutions (formerly called Semiconductor) and Semiconductor Fabrication Solutions (formerly called Material and Substrate). Maximum revenue is generated from Thermal Processing Solutions. Maximum revenue is from Asia Region.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.